

Russia Monoclonal Antibodies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

Market Report | 2024-11-04 | 123 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User \$2550.00
- Multi User \$3750.00
- Enterprise User \$5050.00

Report description:

Russia Monoclonal Antibodies Market was valued at approximately USD 2.5 billion in 2023 and is expected to experience a compound annual growth rate (CAGR) of 13.3% from 2024 to 2032. Monoclonal antibodies (mAbs) are laboratory-engineered molecules designed to act as artificial antibodies, binding to specific antigens, often proteins on cell surfaces, with high precision. These antibodies are derived from identical immune cells cloned from a single parent, ensuring uniform targeting of the same antigen.

One of the key factors driving the market's growth is the rising incidence of chronic and infectious diseases in Russia. Chronic diseases, especially cardiovascular conditions, continue to be a significant health burden in the country, contributing heavily to mortality rates. This increasing prevalence of diseases highlights the need for more advanced and targeted therapies, including monoclonal antibodies, to improve patient outcomes.

The market is divided into several types of monoclonal antibodies, including humanized, fully human, chimeric, and others. The humanized monoclonal antibody segment held the largest share of 48.4% in 2023 and is expected to grow substantially in the coming years. Humanization involves replacing most of a mouse antibody's structure with human components while preserving its ability to bind specific antigens. This makes humanized antibodies highly effective in treating a range of conditions like cancer, autoimmune disorders, and infectious diseases, with reduced risks of immune reactions.

In Russia, local manufacturers have focused heavily on developing biosimilars of humanized monoclonal antibodies, contributing to the growth of this segment. The country's increasing healthcare investments and growing emphasis on personalized medicine also fuel the demand for these sophisticated therapies.

The application segment of the market is dominated by oncology, with this area holding a significant share of 39.1% in 2023. Monoclonal antibodies are gaining traction in cancer treatment due to their targeted therapeutic effects. These antibodies help by

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

binding to specific markers on cancer cells, either inhibiting tumor growth, triggering cell death, or enhancing the body's immune system to fight cancer more effectively.

In terms of end users, hospitals dominate the market with a share of 52% in 2023. Hospitals are central to the distribution and use of monoclonal antibodies, utilizing them for both diagnostic and treatment purposes. The reliance on these antibodies for various medical procedures, such as blood typing and organ transplant matching, is increasing, further driving the demand for monoclonal antibodies in healthcare settings.

Public procurement of biologics, including monoclonal antibodies, makes up a significant portion of Russia's overall medicine procurement, further boosting the market's growth. This trend, combined with the growing demand for advanced medical therapies, is expected to continue fueling the monoclonal antibody market in Russia.

Table of Contents:

Report Content

Chapter 1 Methodology & Scope

1.1 Market scope & definitions

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates & calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Increasing government focus on localizing pharmaceutical production

3.2.1.2 Increasing prevalence of chronic and infectious diseases

3.2.1.3 Rising investment in healthcare infrastructure and research

3.2.2 Industry pitfalls & challenges

3.2.2.1 Lack of a comprehensive regulatory framework for biosimilars and biologics

3.2.2.2 High costs associated with monoclonal antibody production and procurement

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Pipeline analysis

3.6 Future market trends

3.7 Porter's analysis

3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
- Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 (\$ Mn)
 - 5.1 Key trends
 - 5.2 Humanized
 - 5.3 Fully human
 - 5.4 Chimeric
 - 5.5 Other types
- Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 (\$ Mn)
 - 6.1 Key trends
 - 6.2 Oncology
 - 6.3 Autoimmune diseases
 - 6.4 Infectious diseases
 - 6.5 Other applications
- Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 (\$ Mn)
 - 7.1 Key trends
 - 7.2 Hospitals
 - 7.3 Specialty centers
 - 7.4 Other end users
- Chapter 8 Company Profiles
 - 8.1 AbbVie
 - 8.2 Alexion Pharmaceuticals
 - 8.3 Amgen
 - 8.4 Boehringer Ingelheim International
 - 8.5 BIOCAD
 - 8.6 Biogen
 - 8.7 Bristol Myers Squibb
 - 8.8 Eli Lilly and Company
 - 8.9 F. Hoffmann-La Roche
 - 8.10 Generium
 - 8.11 GlaxoSmithKline
 - 8.12 Johnson & Johnson
 - 8.13 Merck
 - 8.14 Nanolek
 - 8.15 Novartis
 - 8.16 Pfizer
 - 8.17 Regeneron Pharmaceuticals
 - 8.18 R-Pharm
 - 8.19 Sanofi
 - 8.20 Takeda Pharmaceutical Company

Russia Monoclonal Antibodies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

Market Report | 2024-11-04 | 123 pages | Global Market Insights

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$2550.00
	Multi User	\$3750.00
	Enterprise User	\$5050.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com